Cihan Gani1, Carla Coackley2, Ramya Kumareswaran2, Christina Schütze3, Mechthild Krause3, Gaetano Zafarana2, Robert G Bristow4. 1. Princess Margaret Cancer Centre (Radiation Medicine Program, University Health Network), Toronto, Canada; Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Canada; Department of Radiation Oncology, University Hospital of Tuebingen, Germany. 2. Princess Margaret Cancer Centre (Radiation Medicine Program, University Health Network), Toronto, Canada; Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Canada. 3. OncoRay - National Centre for Radiation Research in Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden and Helmholtz-Zentrum Dresden-Rossendorf, Germany; Department of Radiation Oncology, Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Germany; German Cancer Consortium (DKTK), Site Dresden and German Cancer Research Center (DKFZ), Heidelberg, Germany. 4. Princess Margaret Cancer Centre (Radiation Medicine Program, University Health Network), Toronto, Canada; Departments of Radiation Oncology and Medical Biophysics, University of Toronto, Canada. Electronic address: rob.bristow@rmp.uhn.on.ca.
Abstract
BACKGROUND AND PURPOSE: Pre-clinical data have shown that PARP inhibitors (PARPi) may increase the efficacy of radiotherapy in prostate cancer. However, it is uncertain as to whether PARPi lead to clonogenic kill when combined with radiotherapy (RT). MATERIAL AND METHODS: We tested the PARP inhibitor AZD-2281 as a radiosensitizing agent under oxic and hypoxic conditions for clonogenic survival in vitro and in vivo using the human prostate cancer cell line, 22Rv1. In addition, the effects of PARPi+RT on normal tissue were investigated using a crypt clonogenic assay. RESULTS: AZD-2281 inhibited cellular PARP activity under both oxic and hypoxic conditions. The addition of AZD-2281 radiosensitized 22Rv1 cells under oxia, acute hypoxia and chronic hypoxia in vitro. The combination of AZD-2281 with fractionated radiotherapy resulted in a significant growth delay and clonogenic kill in vivo. No increased gut toxicity was observed using this combined PARPi+radiotherapy regimen. CONCLUSIONS: This is the first preclinical study to demonstrate direct clonogenic kill in vivo by the addition of AZD-2281 to radiotherapy. As we did not observe gut toxicity, the use of PARPi in the context of prostate cancer radiotherapy warrants further investigation in clinical trials.
BACKGROUND AND PURPOSE: Pre-clinical data have shown that PARP inhibitors (PARPi) may increase the efficacy of radiotherapy in prostate cancer. However, it is uncertain as to whether PARPi lead to clonogenic kill when combined with radiotherapy (RT). MATERIAL AND METHODS: We tested the PARP inhibitor AZD-2281 as a radiosensitizing agent under oxic and hypoxic conditions for clonogenic survival in vitro and in vivo using the humanprostate cancer cell line, 22Rv1. In addition, the effects of PARPi+RT on normal tissue were investigated using a crypt clonogenic assay. RESULTS:AZD-2281 inhibited cellular PARP activity under both oxic and hypoxic conditions. The addition of AZD-2281 radiosensitized 22Rv1 cells under oxia, acute hypoxia and chronic hypoxia in vitro. The combination of AZD-2281 with fractionated radiotherapy resulted in a significant growth delay and clonogenic kill in vivo. No increased gut toxicity was observed using this combined PARPi+radiotherapy regimen. CONCLUSIONS: This is the first preclinical study to demonstrate direct clonogenic kill in vivo by the addition of AZD-2281 to radiotherapy. As we did not observe gut toxicity, the use of PARPi in the context of prostate cancer radiotherapy warrants further investigation in clinical trials.
Authors: John T Poirier; Julie George; Taofeek K Owonikoko; Anton Berns; Elisabeth Brambilla; Lauren A Byers; David Carbone; Huanhuan J Chen; Camilla L Christensen; Caroline Dive; Anna F Farago; Ramaswamy Govindan; Christine Hann; Matthew D Hellmann; Leora Horn; Jane E Johnson; Young S Ju; Sumin Kang; Mark Krasnow; James Lee; Se-Hoon Lee; Jonathan Lehman; Benjamin Lok; Christine Lovly; David MacPherson; David McFadden; John Minna; Matthew Oser; Keunchil Park; Kwon-Sik Park; Yves Pommier; Vito Quaranta; Neal Ready; Julien Sage; Giorgio Scagliotti; Martin L Sos; Kate D Sutherland; William D Travis; Christopher R Vakoc; Sarah J Wait; Ignacio Wistuba; Kwok Kin Wong; Hua Zhang; Jillian Daigneault; Jacinta Wiens; Charles M Rudin; Trudy G Oliver Journal: J Thorac Oncol Date: 2020-02-01 Impact factor: 15.609
Authors: Yanyan Jiang; Jennifer Martin; Maryam Alkadhimi; Kay Shigemori; Paul Kinchesh; Stuart Gilchrist; Veerle Kersemans; Sean Smart; James M Thompson; Mark A Hill; Mark J O'Connor; Barry R Davies; Anderson J Ryan Journal: Br J Cancer Date: 2021-03-19 Impact factor: 7.640
Authors: Ines Lohse; Ramya Kumareswaran; Pinjiang Cao; Bethany Pitcher; Steven Gallinger; Robert G Bristow; David W Hedley Journal: PLoS One Date: 2016-12-29 Impact factor: 3.240
Authors: Naz Chaudary; Melania Pintilie; David Hedley; Richard P Hill; Michael Milosevic; Helen Mackay Journal: Br J Cancer Date: 2016-11-22 Impact factor: 7.640
Authors: Jennifer M J Jongen; Lizet M van der Waals; Kari Trumpi; Jamila Laoukili; Niek A Peters; Susanne J Schenning-van Schelven; Klaas M Govaert; Inne H M Borel Rinkes; Onno Kranenburg Journal: Oncotarget Date: 2017-09-21